Electrophysiology Devices Market to Grow at 10.8% CAGR till 2027; Steadily Rising Demand for Diagnostic Catheters to Foster Market Growth

The global electrophysiology devices market size is projected to reach USD 9.71 billion by 2027 owing to evolving healthcare facilities in emerging economies, finds Fortune Business Insights™ in its report, titled “Electrophysiology Devices Market Size, Share & COVID-19 Impact Analysis, Type (Ablation Catheters, Diagnostic Catheters, Mapping Systems, Accessories, and Others), By Application (Atrial Fibrillation, Supraventricular Tachycardia (SVT), Ventricular Tachycardia, and Others), By End User (Hospitals & ASCs, and Specialty Clinics & Diagnostic Centers), and Regional Forecast, 2020-2027”. The report states that the value of the market stood at USD 5.10 billion in 2019 and is expected to register a CAGR of 10.8% from 2020 to 2027.

The outbreak of the COVID-19 pandemic is anticipated to have a moderate impact on the electrophysiology devices market growth on account of drastic fall in hospital visits of patients with heart disorders. The fear of contracting the infection and prioritization of hospital resources for coronavirus patients are two prominent factors that are affecting the growth of this market.

Boston Scientific Introduces Novel DIRECTSENSE™ Technology

Boston Scientific, the leading American medical devices manufacturer, launched a first-of-its-kind tool for monitoring the effect of radiofrequency energy delivered during cardiac ablation procedures called DIRECTSENSE™ Technology in June 2020. Cleared by the US Food and Drug Administration (FDA) in April, the next-gen technology is currently the only device that can detect and monitor changes in local electrical resistance occurring upon the application of the INTELLANAV™ ablation catheter. This will enable physicians and health workers to accurately measure the effect of therapy during an ablation, a delicate procedure which is conducted on the heart to eliminate heart tissue that is causing abnormal rhythms in the heart.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/electrophysiology-devices-market-101730

Rising Instances of Product Recalls to Impede Market Growth

Electrophysiology devices such as pacemakers and ablation catheters are designed to prevent adverse events in heart patients. Some of these products, however, have either been unable to deliver the desired results or have not conformed to regulatory norms or both, forcing companies to recall them from the market. The worrying part is the increasing frequency of such recalls. For example, in July 2017, the US FDA directed Sterilmed to recall its unexpired EP Ablation Cables as they did not adhere to FDA’s premarket review and approval norms. In February 2019, Stryker voluntarily called back some of the Lifepak defibrillators in response to reports of an issue in the devices which was causing them to malfunction and not deliver the required therapy. A more recent incident involved Medtronic, whose pacemaker had battery and wire defects that led to serious side effects in patients, compelling the FDA to order the company to recall its product in February 2020. These instances are expected to hamper the growth of this market.

Regulatory Backing to Innovative Solutions to Make Competition Dynamic

With the prevalence of complex heart diseases rising worldwide, regulatory authorities are taking proactive measures to ensure that innovative products and solutions receive timely approvals. As a result, leading players in this market are intensely engaging in R&D activities to design, develop, and launch next-gen solutions and advance treatments powered by electrophysiology devices. However, the competition in this market is currently monopolized by large, veteran companies such as Boston Scientific that have a well-entrenched presence in the medical devices industry.

Industry Development:

• January 2019: The US FDA green lit Abbott’s TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™. The device is engineered to enable physicians to accurately and efficiently treat atrial fibrillation (AFib).

List of Key Companies Profiled in this Market Report:

• AngioDynamics (New York, U.S.)


• Stereotaxis, Inc. (Missouri, U.S.)


• Boston Scientific Corporation (Massachusetts, U.S.)


• Abbott (Chicago, U.S.)


• Biotronik, Inc. (Berlin, Germany)


• AtriCure, Inc. (Ohio, U.S.)         


• Johnson & Johnson Services, Inc. (New Jersey, U.S.)


• Medtronic (Dublin, Ireland)

Further Report Findings:

• Growing reliance on ablation procedures for treating AFib will be a key factor in bolstering the growth of the ablation catheters segment. In 2019, the segment led the market with a share of 37.4%.


• North America is expected to dominate the electrophysiology devices market share during the forecast period owing to supportive health reimbursement policies. The region’s market size in 2019 stood at USD 1.82 billion.


• The Middle East & Africa and Latin America are anticipated to present lucrative opportunities as the market in these regions is largely underpenetrated.  

Table of Segmentation: